泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301230 泓博医药

已收盘 05-15 15:00:00

{"stockData":{"symbol":"301230","market":"SZ","secType":"STK","nameCN":"泓博医药","latestPrice":39.22,"timestamp":1778828613000,"preClose":40.49,"halted":0,"volume":6698423,"delay":0,"changeRate":-0.0314,"floatShares":126000000,"shares":140000000,"eps":0.3303,"marketStatus":"已收盘","change":-1.27,"latestTime":"05-15 15:00:00","open":40.39,"high":41.28,"low":38.8,"amount":268000000,"amplitude":0.0612,"askPrice":39.24,"askSize":11,"bidPrice":39.22,"bidSize":355,"shortable":0,"etf":0,"ttmEps":0.3303,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"adjPreClose":40.49,"symbolType":"stock","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":44.54,"lowLimit":36.44,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":139586605,"isCdr":false,"pbRate":5.49,"roa":"--","peRate":118.740539,"roe":"2.34%","epsLYR":0.25,"committee":0.201201,"marketValue":5475000000,"turnoverRate":0.0533,"status":1,"floatMarketCap":4927000000},"requestUrl":"/m/hq/s/301230/wiki","defaultTab":"wiki","newsList":[{"id":"2635038798","title":"泓博医药（301230）披露2025年度网上业绩说明会公告，5月15日股价下跌3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635038798","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635038798?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:14","pubTimestamp":1778854464,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，泓博医药报收于39.22元，较前一交易日下跌3.14%，最新总市值为54.75亿元。公司于近日披露《关于举行2025年度网上业绩说明会的公告》。公告显示，上海泓博智源医药股份有限公司已于2026年4月29日披露《2025年年度报告》及摘要。公司将于2026年5月22日15:00-16:00在全景网举行2025年度网上业绩说明会，投资者可通过全景网“投资者关系互动平台”参与。公司现面向投资者提前征集问题，征集截止时间为2026年5月21日15:00。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500044010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635784287","title":"泓博医药：截至2026年5月8日股东户数为22,920户","url":"https://stock-news.laohu8.com/highlight/detail?id=2635784287","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635784287?lang=zh_cn&edition=full","pubTime":"2026-05-15 09:15","pubTimestamp":1778807733,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)05月14日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好，请问截止至2026年5月10日收盘公司股东人数为多少，谢谢！泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年5月8日（交易日），公司的股东户数为22,920户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500009568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635479242","title":"5月14日泓博医药跌7.41%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635479242","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635479242?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:42","pubTimestamp":1778748147,"startTime":"0","endTime":"0","summary":"证券之星消息，5月14日泓博医药跌7.41%，收盘报40.49元，换手率6.9%，成交量8.66万手，成交额3.67亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为5.33亿元，最新净值1.1879，较上一交易日上涨0.92%，近一年上涨9.32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400028876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633125621","title":"泓博医药（301230）披露关于认购基金份额暨关联交易并完成工商变更登记的公告，5月7日股价上涨2.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633125621","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633125621?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:58","pubTimestamp":1778147933,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘，泓博医药报收于43.63元，较前一交易日上涨2.61%，最新总市值为60.9亿元。近日，泓博医药发布《关于认购基金份额暨关联交易并完成工商变更登记的公告》。该基金主要投资于生物医药健康产业，公司与普通合伙人及其他有限合伙人已签署合伙协议，并完成工商变更登记。本次投资构成与关联方开原亨泰营养科技有限公司的共同投资，属于关联交易，已履行董事会审议程序，无需提交股东大会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700030474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632367461","title":"每周股票复盘：泓博医药（301230）Q1净利增98.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632367461","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632367461?lang=zh_cn&edition=full","pubTime":"2026-05-03 03:01","pubTimestamp":1777748474,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，泓博医药报收于41.4元，较上周的43.36元下跌4.52%。本周关注点业绩披露要点：泓博医药2026年一季度归母净利润同比增长98.59%。股本股东变化截至2026年4月10日，泓博医药股东户数为2.39万户，较3月31日减少1091.0户，减幅为4.36%。预计派发现金股利约27,508,081元（含税），转增后总股本增至180,848,726股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300000555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631532389","title":"图解泓博医药一季报：第一季度单季净利润同比增长98.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631532389","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631532389?lang=zh_cn&edition=full","pubTime":"2026-04-29 06:17","pubTimestamp":1777414639,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药2026年一季报显示，一季度公司主营收入1.72亿元，同比上升1.69%；归母净利润2377.92万元，同比上升98.59%；扣非净利润645.66万元，同比下降33.32%；负债率21.73%，投资收益680.71万元，财务费用374.47万元，毛利率31.92%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900014775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629201540","title":"4月22日泓博医药涨9.80%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629201540","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629201540?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:34","pubTimestamp":1776846897,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日泓博医药涨9.80%，收盘报43.82元，换手率11.11%，成交量13.96万手，成交额5.76亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.1122，较上一交易日下跌1.16%，近一年上涨10.67%。该公募基金现任基金经理为龙宇飞。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200037904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628798976","title":"股市必读：泓博医药(301230)股东户数2.39万户，较上期减少4.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628798976","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628798976?lang=zh_cn&edition=full","pubTime":"2026-04-20 01:37","pubTimestamp":1776620227,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，泓博医药报收于40.06元，下跌2.36%，换手率5.56%，成交量6.99万手，成交额2.8亿元。股本股东变化股东户数变动近日泓博医药披露，截至2026年4月10日公司股东户数为2.39万户，较3月31日减少1091.0户，减幅为4.36%。户均持股数量由上期的5578.0股增加至5832.0股，户均持股市值为23.25万元。根据中登公司下发的股东名册，截至2026年4月10日（交易日），公司的股东户数为23,935户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000000807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628796282","title":"泓博医药：截至2026年4月10日股东户数为23,935户","url":"https://stock-news.laohu8.com/highlight/detail?id=2628796282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628796282?lang=zh_cn&edition=full","pubTime":"2026-04-17 16:24","pubTimestamp":1776414264,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)04月17日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问截止到2026年4月15日收盘公司股东人数是多少？谢谢！泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年4月10日（交易日），公司的股东户数为23,935户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700030461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624657429","title":"泓博医药：公司与药石科技未开展相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2624657429","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624657429?lang=zh_cn&edition=full","pubTime":"2026-04-03 19:38","pubTimestamp":1775216280,"startTime":"0","endTime":"0","summary":"证券日报网讯4月3日，泓博医药在互动平台回答投资者提问时表示，截至目前，公司与药石科技未开展相关合作。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-03/doc-inhtfrev3672977.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-03/doc-inhtfrev3672977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301230","BK0229","300725","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624656576","title":"泓博医药：截至2026年3月31日股东户数为25,026户","url":"https://stock-news.laohu8.com/highlight/detail?id=2624656576","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624656576?lang=zh_cn&edition=full","pubTime":"2026-04-03 16:54","pubTimestamp":1775206443,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)04月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问截止到2026年3月31日公司股东人数是多少？谢谢！泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年3月31日(交易日)，公司的股东户数为25,026户。感谢关注！为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260403/32124756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624765514","title":"4月3日泓博医药跌7.58%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624765514","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624765514?lang=zh_cn&edition=full","pubTime":"2026-04-03 16:17","pubTimestamp":1775204275,"startTime":"0","endTime":"0","summary":"证券之星消息，4月3日泓博医药跌7.58%，收盘报40.99元，换手率11.85%，成交量14.89万手，成交额6.25亿元。重仓泓博医药的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.1331，较上一交易日下跌0.99%，近一年上涨2.89%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300031342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624330595","title":"4月1日泓博医药涨7.83%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624330595","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624330595?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:19","pubTimestamp":1775031553,"startTime":"0","endTime":"0","summary":"证券之星消息，4月1日泓博医药涨7.83%，收盘报43.79元，换手率18.03%，成交量22.65万手，成交额9.51亿元。重仓泓博医药的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.0955，较上一交易日下跌1.32%，近一年上涨0.87%。该公募基金现任基金经理为龙宇飞。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100029177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623239700","title":"3月30日泓博医药涨6.86%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623239700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623239700?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:29","pubTimestamp":1774859381,"startTime":"0","endTime":"0","summary":"证券之星消息，3月30日泓博医药涨6.86%，收盘报39.43元，换手率14.65%，成交量18.41万手，成交额7.35亿元。重仓泓博医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.102，较上一交易日上涨2.52%，近一年上涨0.38%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000021618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622361849","title":"3月27日泓博医药涨5.52%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622361849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622361849?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:18","pubTimestamp":1774599508,"startTime":"0","endTime":"0","summary":"证券之星消息，3月27日泓博医药涨5.52%，收盘报36.9元，换手率5.08%，成交量6.38万手，成交额2.31亿元。重仓泓博医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.0749，较上一交易日下跌1.65%，近一年下跌2.1%。该公募基金现任基金经理为龙宇飞。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621059046","title":"泓博医药：截至2026年3月20日股东户数为19,571户","url":"https://stock-news.laohu8.com/highlight/detail?id=2621059046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621059046?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:15","pubTimestamp":1774336524,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)03月24日在投资者关系平台上答复投资者关心的问题。投资者提问：公司最新股东人数泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年3月20日（交易日），公司的股东户数为19,571户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400019846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620316172","title":"彩讯股份：公司暂未与泓博医药合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2620316172","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620316172?lang=zh_cn&edition=full","pubTime":"2026-03-18 17:48","pubTimestamp":1773827300,"startTime":"0","endTime":"0","summary":"证券之星消息，彩讯股份(300634)03月18日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，注意到公司在布局AI制药相关方面，也注意到公司在和泓博医药有AI制药AI大模型相关的合作，泓博医药可以说是国内AI制药第一股，现在市值这么低潜力这么巨大，公司为什么不直接控股或者收购呢彩讯股份回复：尊敬的投资者，您好！公司暂未与泓博医药合作，暂无上述安排，请以公司公告为准。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800032428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0231","300634","301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620427884","title":"泓博医药：围绕相关技术方向构建了以DiOrion平台为核心的药物研发体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620427884?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:52","pubTimestamp":1773751961,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药03月16日在投资者关系平台上答复投资者关心的问题。公司围绕相关技术方向构建了以DiOrion平台为核心的药物研发体系，覆盖靶点发现、分子设计与优化、成药性预测等关键环节。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700039720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620942738","title":"凯普生物：公司与您提及的泓博医药暂无相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620942738?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:52","pubTimestamp":1773751934,"startTime":"0","endTime":"0","summary":"证券之星消息，凯普生物(300639)03月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，注意到公司在布局AI制药相关方面，也注意到公司在和泓博医药有AI制药AI大模型相关的合作，泓博医药可以说是国内AI制药第一股，现在市值这么低潜力这么巨大，公司为什么不直接控股或者收购呢凯普生物回复：您好，感谢您的关注。公司与您提及的泓博医药暂无相关合作，关于公司的对外投资情况请留意公司的相关公告及定期报告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700039681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0239","BK0046","BK0042","300639","BK0132","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619327964","title":"泓博医药：公司目前的DiOrion平台主要由公司自主研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2619327964","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619327964?lang=zh_cn&edition=full","pubTime":"2026-03-16 15:07","pubTimestamp":1773644835,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药03月15日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，想了解公司与深势科技目前合作的具体进展： 1.双方在AI药物研发、分子模拟、Hermite平台、Uni-FEP计算等方面的合作推进到哪一阶段？公司与深势科技此前有过合作，相关技术也在公司早期项目中进行了应用。公司目前的DiOrion平台主要由公司自主研发，双方并未开展合作研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600014261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779035003934,"stockEarnings":[{"period":"1week","weight":-0.0802},{"period":"1month","weight":-0.045},{"period":"3month","weight":-0.1325},{"period":"6month","weight":0.2041},{"period":"1year","weight":0.3506},{"period":"ytd","weight":0.3158}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海泓博智源医药股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"22920人(较上一季度增加0.81%)","perCapita":"5480股","listingDate":"2022-11-01","address":"上海市浦东新区庆达路315号23幢","registeredCapital":"13958万元","survey":"　　上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是药物化学、合成化学、药物代谢动力学、工艺化学、工艺开发、药学研究、定制化生产、自主产品生产。","listedPrice":40},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泓博医药,301230,泓博医药股票,泓博医药股票老虎,泓博医药股票老虎国际,泓博医药行情,泓博医药股票行情,泓博医药股价,泓博医药股市,泓博医药股票价格,泓博医药股票交易,泓博医药股票购买,泓博医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}